• Profile
Close

Cabotegravir for HIV prevention in cisgender men and transgender women

New England Journal of Medicine Aug 16, 2021

Landovitz RJ, Donnell D, Clement ME, et al. - Relative to providing daily oral tenofovir disoproxil fumarate–emtricitabine (TDF–FTC), long-acting injectable cabotegravir (CAB-LA, an integrase strand-transfer inhibitor [INSTI]) was identified as superior in preventing HIV infection among men who have sex with men (MSM) and transgender women.

  • A randomized, double-blind, double-dummy, noninferiority trial.

  • At-risk cisgender MSM and at-risk transgender women who have sex with men were administered CAB-LA at a dose of 600 mg, intramuscularly every 8 weeks, with daily oral TDF–FTC.

  • The intention-to-treat population included 4,566 participants.

  • From the United States, there were 1,698 participants, 845 of whom (49.8%) were identified as Black.

  • Fifty-two participants had occurrence of incident HIV infection: 13 in the cabotegravir group (incidence, 0.41 per 100 person-years) and 39 in the TDF–FTC group (incidence, 1.22 per 100 person-years).

  • 81.4% of the participants in the cabotegravir group and 31.3% of those in the TDF–FTC group reported injection-site reactions.

  • Researchers identified INSTI resistance and delays in the detection of HIV infection in the participants in whom HIV infection was diagnosed following exposure to CAB-LA.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay